|
1
| A/H1N1 Vaccine | Novartis | SEP-2009 |
|
|
2
| Ad26.ENV.01 | Crucell Holland BV | NOV 2007 |
|
|
3
| Ad5 HIV-1 gag vaccine and MRKAd5 HIV-1 gag vaccine | Merck & Co. | JUN 2007 |
|
|
4
| Ad5HVR48.ENVA.01 | Crucell Holland | APR 2008 |
|
|
5
| Genevax- IL-12-6285 and -4532 | Profectus | MAR 2009 |
|
|
6
| HIV-1 Plasmid DNA Vaccine, pGA2/JS7and MVA HIV62 (Combined IB) | GeoVax | OCT 2008 |
|
|
7
| LC002 | Genetic Immunity | JUL 2009 |
|
|
8
| MRCKAD5HIV-1 GAG/POL/NEF | Merck & Co. | JUN-2007 |
|
|
9
| PENNVAX-B | University of Pennsylvania | MAR-2007 |
|
|
10
| PENNVAX-B + Ep | VGX Pharmaceuticals | MAY 2009 |
|
|
11
| pIl15EAM | University of Pennsylvania | MAR-2007 |
|
|
12
| Rotavirus Vaccine (RotaTeq) | Merck | OCT 2009 |
|
|
13
| SAAVI DNA-C2 and SAAVI MVA-C | NIAID/SAAVI | DEC 2009 |
|
|
14
| VRC-HIVADV014-00-VP (Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine) | VRC/NIAID/NIH | AUG 2009 |
|
|
15
| VRC-HIVADV014-00-VP and VRC-HIVDNA016-00-VP Combination | VRC/NIAID/NIH | JAN 2009 |
|
|
16
| VRC-HIVADV027-00-VP (Recombinant Adenoviral Serotype 35) | VRC/NIAID/NIH | SEP 2009 |
|